Cover Image
市場調查報告書

高血壓治療藥的全球市場:2016∼2020年

Global Hypertension Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 299263
出版日期 內容資訊 英文 87 Pages
訂單完成後即時交付
價格
Back to Top
高血壓治療藥的全球市場:2016∼2020年 Global Hypertension Drugs Market 2016-2020
出版日期: 2016年04月13日 內容資訊: 英文 87 Pages
簡介

全球高血壓治療藥市場,預計2016∼2020年,以年複合成長率0.93%擴大。高血壓由於是血管內壁受到過度壓力,分類為肺動脈高血壓和全身性高血壓。

本報告提供全球高血壓治療藥市場現狀與至2020年的成長預測,市場趨勢與課題,各地區趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 心血管藥物市場

  • 全球醫藥品市場
  • 全球心血管藥物市場

第6章 概要:高血壓

  • 全身性高血壓
  • 肺動脈高血壓

第7章 流行病學及經濟負擔

第8章 產品研發線

第9章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第10章 類型場市場區隔

  • 全身性高血壓藥物市場
  • 肺動脈高血壓藥物市場

第11章 各類藥物市場區隔

第12章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第13章 推動市場的要素

第14章 促進要素的影響

第15章 市場課題

第16章 促進要素與課題的影響

第17章 市場趨勢

第18章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年
  • Novartis
  • 第一三共株式會社
  • Actelion Pharmaceuticals
  • Boehringer Ingelheim
  • Sanofi
  • AstraZeneca
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR9233

About Hypertension Drugs

Hypertension, or high blood pressure (BP), develops when there is too much pressure against the inner walls of blood vessels. Depending on the pressure exerted, hypertension can be classified as:

  • PAH
  • Systemic hypertension (commonly referred to as hypertension)

PAH, high BP in the arteries that carry blood from the heart to the lungs, occurs when blood vessels narrow, making blood flow difficult. This creates pressure on the heart's right ventricle, which increases in size and becomes weaker due to the excess load, leading to heart failure. The normal pulmonary arterial pressure at rest is 14 mmHg and increases from 25 mmHg to 30 mmHg.

Systemic hypertension occurs when blood vessels that supply oxygenated blood to the body become narrower, creating pressure on the right side of the heart. Hypertension can lead to damaged organs and illnesses such as renal failure (kidney failure), aneurysm, heart failure, stroke, or heart attack. Hypertension is classified into two types:

  • Primary or essential hypertension: It is defined as high BP with no known cause, and includes around 90%-95% of all hypertension cases
  • Secondary hypertension: It is high BP with a known direct cause, including kidney disease, tumors, or birth control pills, and includes 5%-10% of all hypertension cases

Technavio's analysts forecast the global hypertension drugs market to decline at a CAGR of (0.93) % during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypertension drugs market for 201652020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent hypertension and pulmonary arterial hypertension (PAH).

The market is divided into the following segments based on geography:

  • Americas
  • EMEA
  • APAC

Technavio's report, Global Hypertension Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Actelion Ltd.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Daiichi Sankyo Company, Ltd.
  • Novartis AG
  • Sanofi SA

Other Prominent Vendors

  • Actelion Pharmaceuticals
  • Arena Pharmaceuticals
  • Asahi Kasei
  • Bayer HealthCare
  • Bellerophon Therapeutics
  • Bial
  • CJ HealthCare
  • Conatus Pharmaceuticals
  • Daiichi Sankyo
  • Deka Pharmaceuticals
  • Dong-A ST
  • Eiger BioPharmaceuticals
  • Forest Laboratories
  • Gilead Sciences
  • HanAll BioPharma
  • Hanmi Pharmaceutical
  • Johnson & Johnson
  • LG Life Sciences
  • Lung Biotechnology
  • Lupin Pharmaceuticals
  • Mast Therapeutics
  • Merck
  • Northern Therapeutics
  • Ono Pharmaceutical
  • Pfizer
  • PhaseBio
  • Pluristem Therapeutics
  • Quantum Genomics
  • Radikal Therapeutics
  • Reata Pharmaceuticals
  • Serodus
  • sigma-tau i.f.r
  • SteadyMed Therapeutics
  • Suda
  • Sun Pharmaceutical Industries
  • Symplmed Pharmaceuticals
  • Takeda Pharmaceuticals
  • United Therapeutics
  • Valeant Pharmaceuticals
  • XOMA
  • Yuhan

Market driver

  • Growing older population
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries of major drugs
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Cardiovascular drugs market

  • Global pharmaceuticals market
  • Global cardiovascular drugs market

PART 06: Overview: Hypertension

  • Systemic hypertension
  • PAH

PART 07: Epidemiology and economic burden

  • Economic burden

PART 08: Pipeline portfolio

PART 09: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 10: Market segmentation by type

  • Global systemic hypertension drugs market
  • Global PAH drugs market

PART 11: Market segmentation by drug class

  • Systemic hypertension
  • PAH

PART 12: Geographical segmentation

  • Global hypertension drugs market by geographical segmentation 2015-2020
  • Hypertension drugs market in Americas
  • Hypertension drugs market in EMEA
  • Hypertension drugs market in APAC

PART 13: Market drivers

  • Growing older population
  • Rise in sedentary lifestyle
  • High prevalence of chronic conditions
  • Patient assistance programs

PART 14: Impact of drivers

PART 15: Market challenges

  • Patent expiries of major drugs
  • Adverse effects
  • Poor patient compliance
  • Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Increase in awareness
  • Increased focus on combination therapies
  • Intense competition among vendors
  • Strategic alliances

PART 18: Vendor landscape

  • Competitive scenario
  • Market share 2015
  • Novartis
  • Daiichi Sankyo
  • Actelion Pharmaceuticals
  • Boehringer Ingelheim
  • Sanofi
  • AstraZeneca
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key buying criteria for drugs that treat hypertension
  • Exhibit 03: Patent expiries of major cardiovascular drugs
  • Exhibit 04: Global cardiovascular drugs market by generic and branded drugs sales 2015
  • Exhibit 05: Top 10 companies in global cardiovascular drugs market 2014
  • Exhibit 06: Pathophysiology of hypertension
  • Exhibit 07: Treatment algorithm for hypertension
  • Exhibit 08: Prevalence of PAH by cause
  • Exhibit 09: Projected prevalence of CVDs in US 2010-2030 (% of population)
  • Exhibit 10: Prevalence of hypertension in US population 2010-2030 (% of population)
  • Exhibit 11: Projected direct and indirect burden of hypertension in US 2010-2030 ($ billions)
  • Exhibit 12: Projected mortality trend for CVDs globally 2015 and 2030
  • Exhibit 13: Pipeline portfolio: Global systemic hypertension drugs
  • Exhibit 14: Pipeline portfolio: Global PAH drugs
  • Exhibit 15: Market share of global hypertension drugs in global pharmaceutical market 2015
  • Exhibit 16: Global hypertension drugs market 2015-2020 ($ billions)
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Global hypertension drugs market segmentation by type 2015
  • Exhibit 19: Global systemic hypertension drugs market 2015-2020 ($ billions)
  • Exhibit 20: Global PAH drugs market 2015-2020 ($ billions)
  • Exhibit 21: Segmentation of global hypertension drugs market by drug class
  • Exhibit 22: Global systemic hypertension drugs market share by drug class 2015
  • Exhibit 23: Global PAH drugs market share by drug class 2015
  • Exhibit 24: Segmentation of global hypertension drugs market based on geography 2015
  • Exhibit 25: Hypertension drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 26: Percentage share of hypertension drugs market by geography 2015-2020
  • Exhibit 27: Hypertension drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 28: Hypertension drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 29: Hypertension drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 30: Global hypertension drugs market: YoY growth rate and revenue based on geography 2015-2020
  • Exhibit 31: Population aged 60 years and over: World, developed, and developing regions ($ millions)
  • Exhibit 32: Impact of drivers
  • Exhibit 33: Impact of drivers and challenges
  • Exhibit 34: Sales of major drugs in global hypertension drugs market 2014 ($ billions)
  • Exhibit 35: Novartis: YoY growth rate and revenue of Diovan 2012-2015 ($ billions)
  • Exhibit 36: Novartis: YoY growth rate and revenue of Exforge 2012-2015 ($ billions)
  • Exhibit 37: Novartis: Key takeaways
  • Exhibit 38: Daiichi Sankyo: YoY growth rate and revenue of Olmetec in Japan 2012-2014 ($ millions)
  • Exhibit 39: Daiichi Sankyo: YoY growth rate and revenue of Olmetec/Olmetec Plus in Europe 2012-2014 ($ millions)
  • Exhibit 40: Daiichi Sankyo: YoY growth rate and revenue of Rezaltas in Japan 2012-2014 ($ millions)
  • Exhibit 41: Daiichi Sankyo: YoY growth rate and revenue of Artist in Japan 2012-2014 ($ millions)
  • Exhibit 42: Daiichi Sankyo: YoY growth rate and revenue of Benicar/Benicar HCT in US 2012-2014 ($ millions)
  • Exhibit 43: Daiichi Sankyo: YoY growth rate and revenue of AZOR in US 2012-2014 ($ millions)
  • Exhibit 44: Daiichi Sankyo: YoY growth rate and revenue of TRIBENZOR in US 2012-2014 ($ millions)
  • Exhibit 45: Daiichi Sankyo: YoY growth rate and revenue of Sevikar in Europe 2012-2014 ($ millions)
  • Exhibit 46: Daiichi Sankyo: YoY growth rate and revenue of Sevikar HCT in Europe 2012-2014 ($ millions)
  • Exhibit 47: Daiichi Sankyo: Key takeaways
  • Exhibit 48: Actelion Pharmaceuticals: YoY growth rate and revenue of Tracleer 2011-2014 ($ billions)
  • Exhibit 49: Actelion Pharmaceuticals: YoY revenue of Opsumit 2013 and 2014 ($ millions)
  • Exhibit 50: Actelion Pharmaceuticals: YoY growth rate and revenue of Ventavis 2011-2014 ($ millions)
  • Exhibit 51: Actelion Pharmaceuticals: YoY growth rate and revenue of Veletri 2011-2014 ($ millions)
  • Exhibit 52: Actelion Pharmaceuticals: Key takeaways
  • Exhibit 53: Boehringer Ingelheim: YoY growth rate and revenue of Micardis 2012-2014 ($ millions)
  • Exhibit 54: Boehringer Ingelheim: Key takeaways
  • Exhibit 55: Sanofi: YoY growth rate and revenue of Aprovel 2012-2014 ($ millions)
  • Exhibit 56: Sanofi: YoY growth rate and revenue of Tritace 2012-2014 ($ millions)
  • Exhibit 57: Sanofi: YoY growth rate and revenue of Lasix 2012-2014 ($ millions)
  • Exhibit 58: Sanofi: Key takeaways
  • Exhibit 59: AstraZeneca: Business segmentation by revenue 2015
  • Exhibit 60: AstraZeneca: YoY growth rate and revenue of Seloken/Toprol 2013-2015 ($ millions)
  • Exhibit 61: AstraZeneca: YoY growth rate and revenue of Atacand 2013-2015 ($ millions)
  • Exhibit 62: AstraZeneca: YoY growth rate and revenue of Tenormin 2012-2014 ($ millions)
  • Exhibit 63: AstraZeneca: Key takeaways
Back to Top